Bristol-Myers Squibb (NYSE:BMY) Shares Sold by First Hawaiian Bank

First Hawaiian Bank trimmed its position in Bristol-Myers Squibb (NYSE:BMY) by 19.2% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 63,031 shares of the biopharmaceutical company’s stock after selling 14,933 shares during the period. First Hawaiian Bank’s holdings in Bristol-Myers Squibb were worth $3,418,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently bought and sold shares of BMY. Envestnet Portfolio Solutions Inc. acquired a new position in Bristol-Myers Squibb in the third quarter valued at approximately $4,499,000. Glenview Trust co boosted its position in shares of Bristol-Myers Squibb by 0.4% during the third quarter. Glenview Trust co now owns 109,894 shares of the biopharmaceutical company’s stock worth $6,378,000 after buying an additional 447 shares during the period. Rathbones Group PLC boosted its position in shares of Bristol-Myers Squibb by 128.6% during the third quarter. Rathbones Group PLC now owns 57,564 shares of the biopharmaceutical company’s stock worth $3,341,000 after buying an additional 32,379 shares during the period. V Square Quantitative Management LLC boosted its position in shares of Bristol-Myers Squibb by 32.1% during the third quarter. V Square Quantitative Management LLC now owns 17,018 shares of the biopharmaceutical company’s stock worth $988,000 after buying an additional 4,140 shares during the period. Finally, Azimuth Capital Investment Management LLC boosted its position in shares of Bristol-Myers Squibb by 1.0% during the third quarter. Azimuth Capital Investment Management LLC now owns 130,362 shares of the biopharmaceutical company’s stock worth $7,566,000 after buying an additional 1,240 shares during the period. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Bristol-Myers Squibb Stock Performance

NYSE BMY opened at $40.81 on Thursday. Bristol-Myers Squibb has a 1 year low of $39.91 and a 1 year high of $66.38. The company has a quick ratio of 0.99, a current ratio of 1.11 and a debt-to-equity ratio of 2.99. The business’s fifty day moving average is $43.89 and its two-hundred day moving average is $48.55.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share for the quarter, topping the consensus estimate of ($4.53) by $0.13. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The firm had revenue of $11.87 billion for the quarter, compared to analysts’ expectations of $11.45 billion. During the same period in the previous year, the company posted $2.05 EPS. The company’s quarterly revenue was up 4.7% compared to the same quarter last year. On average, analysts forecast that Bristol-Myers Squibb will post 0.59 EPS for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, August 1st. Shareholders of record on Friday, July 5th will be given a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 5.88%. The ex-dividend date of this dividend is Friday, July 5th. Bristol-Myers Squibb’s payout ratio is -77.42%.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on BMY. Barclays reduced their price objective on Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating for the company in a research report on Friday, April 26th. William Blair reiterated a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. BMO Capital Markets dropped their target price on Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a report on Friday, April 26th. Societe Generale cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, March 11th. Finally, StockNews.com cut Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Monday. One analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $60.00.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.